Atara Biotherapeutics, INC 8-K filings

Atara Biotherapeutics announced second quarter 2026 financial results and operational progress, including a productive FDA meeting for tabelecleucel and significant cost reductions.

Atara Biotherapeutics has appointed Kevin G. Sarney as interim CFO following the departure of Chief Accounting Officer Yanina Grant-Huerta.

Atara Biotherapeutics appoints Brian Cherry to its Board of Directors and confirms shareholder approval of all 2026 annual meeting proposals.

Atara Biotherapeutics reported Q1 2026 financial results, with a focus on operational progress and a potential path forward for tabelecleucel BLA resubmission with the FDA.

Atara Biotherapeutics provides an update on the regulatory path for tabelecleucel following a Type A meeting with the FDA, indicating a potential pathway for resubmission.

Atara Biotherapeutics has been notified by Nasdaq that it fails to meet the minimum $50 million market value requirement for continued listing.

Atara Biotherapeutics announced its fourth quarter and full year 2025 financial results, reporting net income for the year and extending its cash runway through year-end 2026.

Atara Biotherapeutics announced a scheduled Type A meeting with the FDA to discuss the Complete Response Letter for its tabelecleucel Biologics License Application.

Atara Biotherapeutics' partner, Pierre Fabre Pharmaceuticals, requested a Type A meeting with the FDA to address the Complete Response Letter for tabelecleucel's Biologics License Application.

Atara Biotherapeutics secured an extension for a $9 million milestone payment to HCRx until January 2028, in exchange for issuing warrants to purchase 400,000 shares of common stock.

Atara Biotherapeutics announced the FDA issued a Complete Response Letter for its EBVALLO BLA, citing new concerns about trial adequacy despite prior alignment.

Atara Biotherapeutics amended its commercialization agreement with Pierre Fabre, reducing regulatory milestones by $9 million in exchange for a new $15 million commercial milestone opportunity.

Atara Biotherapeutics reported third-quarter 2025 financial results, highlighted by FDA Priority Review for tab-cel and the transfer of tab-cel activities to Pierre Fabre Laboratories.

Atara Biotherapeutics, Inc. announced a significant workforce reduction impacting approximately 29% of its employees, expecting $1.3 million in related charges.

Atara Biotherapeutics announced a reduction in its Board of Directors from ten to seven members, including three voluntary resignations and a new Board Chair appointment.

Atara Biotherapeutics announced FDA acceptance of its tab-cel BLA with Priority Review, a January 10, 2026 PDUFA date, and resumed evaluation of strategic options.

Atara Biotherapeutics has resubmitted its Biologics License Application for tabelecleucel (Tab-cel) to the U.S. FDA for EBV+ PTLD, a move that could trigger a $40 million milestone payment from Pierre Fabre Laboratories and extends the company's cash runway into the first quarter of 2026.

Atara Biotherapeutics, Inc. announced the results of its 2025 annual meeting of stockholders, where all director nominees were elected, executive compensation was approved on an advisory basis, and stockholders voted for annual advisory votes on executive compensation.

Atara Biotherapeutics has entered into an underwriting agreement for a $16 million registered direct offering of common stock and pre-funded warrants.

Atara Biotherapeutics reports positive Q1 2025 financial results driven by the Pierre Fabre agreement and secures $16 million in funding to extend cash runway into Q1 2026.

Atara Biotherapeutics is reducing its workforce by approximately 30% to focus on strategic priorities, expecting to incur $1.4 million in severance costs.

The FDA has lifted the clinical hold on Atara Biotherapeutics' EBVALLO program and granted a Type A meeting to discuss the path forward for BLA resubmission.

Atara Biotherapeutics amended its commercialization agreement with Pierre Fabre, transferring manufacturing responsibility and reducing potential milestone payments in exchange for Pierre Fabre assuming manufacturing costs and remediation expenses.

Atara Biotherapeutics reports the departure of its CFO and COO, Eric Hyllengren, and the appointment of Yanina Grant-Huerta as the new Chief Accounting Officer, effective March 31, 2025.

Atara Biotherapeutics reports Q4 and full year 2024 financial results, pauses CAR-T programs, and focuses on EBVALLO BLA resubmission.

Atara Biotherapeutics is reducing its workforce by approximately 50% and discontinuing development of ATA3219 and ATA3431 programs.

Atara Biotherapeutics plans to reduce its workforce by approximately 50% and expects to incur $7.5 million in severance costs.

The FDA has placed a clinical hold on Atara Biotherapeutics' EBVALLO and ATA3219 programs due to manufacturing compliance issues at a third-party facility.

Atara Biotherapeutics received a Complete Response Letter from the FDA for its EBVALLO application due to manufacturing inspection findings, while also exploring strategic alternatives and securing a $15 million funding commitment.

Atara Biotherapeutics has amended its bylaws, granting the board of directors greater control over the scheduling and conduct of stockholder meetings and director nominations.